EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

DDAH1 Promotes Cisplatin Chemoresistance in Patients with Locally Advanced Nasopharyngeal Carcinoma via the EGFR‐JAK2‐STAT3 Pathway

Jin-Hao Yang, Li Yuan, Qiu-Yan Chen, Kai-Qi Lan, Liang-Ji Li, Yu-Chen Li, Xiao-Yun Li, Xue-Song Sun, Lin-Quan Tang, Sai-Lan Liu, Hai-Qiang Mai iD

Advanced Science · 2025

DOI: 10.1002/advs.202503647 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Science, 2025. Verfasst von Jin-Hao Yang und 10 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carc…. Hauptthemen laut MEDLINE: Nasopharyngeal Carcinoma, Cisplatin, Drug Resistance, Neoplasm, Amidohydrolases. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cisplatin‐based induction chemotherapy (IC) improves survival in patients with locally advanced nasopharyngeal carcinoma (LANPC). However, ≈30% of patients with LANPC receiving IC develop chemoresistance, and 20% experience disease progression. The relation between chemoresistance and Dimethylarginine dimethylaminohydrolase‐1 (DDAH1) in NPC has not been mentioned in previous studies. To explore the regulatory mechanism and biological function of DDAH1 in cisplatin chemoresistance, NPC cell lines are subjected to overexpression and knockdown of DDAH1 in vitro, with findings further corroborated by in vivo chemosensitivity assays. The predictive value of DDAH1 expression is evaluated for survival and resistance to cisplatin‐based IC in a cohort of 339 patients with LANPC. Overexpression of DDAH1 in NPC cell lines increases cisplatin resistance both in vitro and in vivo through binding to the intracellular domain of epidermal growth factor receptor (EGFR), enhancing its dimerization and phosphorylation, thereby promoting the activation of the JAK2‐STAT3 pathway, which is dependent on EGFR and extracellular ligands and can be weakened by nimotuzumab. Clinically, DDAH1 positivity correlates with unfavorable 3‐year survivals. This study identified DDAH1 as a prognostic marker and a potential therapeutic target for nimotuzumab to overcome treatment failure and chemoresistance in LANPC and other EGFR‐positive cancers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Nasopharyngeal CarcinomaCisplatinDrug Resistance, NeoplasmAmidohydrolasesNasopharyngeal NeoplasmsHumansSTAT3 Transcription FactorErbB ReceptorsJanus Kinase 2FemaleCell Line, TumorSignal TransductionMaleAntineoplastic AgentsMiddle AgedAnimalsMice

Stichwörter der Autor:innen

DDAH1EGFRJAK2‐STAT3 pathwaycisplatin resistancenasopharyngeal carcinomanimotuzumab

Substanzen

CisplatinSTAT3 Transcription FactorErbB ReceptorsSTAT3 protein, humanJanus Kinase 2dimethylargininaseAmidohydrolasesJAK2 protein, humanEGFR protein, humanAntineoplastic Agents

Autor:innen und Institutionen

  • State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Gua…
  • Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060, P. R. China.

ORCID-Profile: Hai-Qiang Mai

Förderung

  • National Key Research and Development Program of China
  • National Natural Science Foundation of China

Zitieren

APA

Yang, J. H., Yuan, L., Chen, Q. Y., Lan, K. Q., Li, L. J., Li, Y. C., Li, X. Y., Sun, X. S., Tang, L. Q., Liu, S. L., & Mai, H. Q. (2025). DDAH1 Promotes Cisplatin Chemoresistance in Patients with Locally Advanced Nasopharyngeal Carcinoma via the EGFR‐JAK2‐STAT3 Pathway. Advanced Science. https://doi.org/10.1002/advs.202503647

Vancouver

Yang JH, Yuan L, Chen QY, Lan KQ, Li LJ, Li YC, et al. DDAH1 Promotes Cisplatin Chemoresistance in Patients with Locally Advanced Nasopharyngeal Carcinoma via the EGFR‐JAK2‐STAT3 Pathway. Advanced Science. 2025. doi:10.1002/advs.202503647

BibTeX
@article{Yang2025,
  author = {Yang, Jin-Hao and Yuan, Li and Chen, Qiu-Yan and Lan, Kai-Qi and Li, Liang-Ji and Li, Yu-Chen and Li, Xiao-Yun and Sun, Xue-Song and Tang, Lin-Quan and Liu, Sai-Lan and Mai, Hai-Qiang},
  title = {DDAH1 Promotes Cisplatin Chemoresistance in Patients with Locally Advanced Nasopharyngeal Carcinoma via the EGFR‐JAK2‐STAT3 Pathway},
  journal = {Advanced Science},
  year = {2025},
  doi = {10.1002/advs.202503647}
}
Kostenlos starten →